What new FDA approval is GSK seeking for Jemperli in rectal cancer?

GSK plans to seek FDA approval to expand Jemperli’s label for patients with specific types of rectal cancer after strong phase 2 trial results. The immunotherapy met its main goal and could represent a breakthrough for a small but clinically important group, positioning Jemperli to strengthen GSK’s oncology portfolio.